Alfonso G. Zulueta - 21 Dec 2023 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Director
Signature
/s/ Wendy Pizarro, Attorney-in-fact
Issuer symbol
CLDI
Transactions as of
21 Dec 2023
Net transactions value
+$10,159
Form type
4
Filing time
04 Jan 2024, 19:55:27 UTC
Previous filing
06 Nov 2023
Next filing
08 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDI Common Stock Award $10,159 +5,644 +4.4% $1.80 133,301 21 Dec 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Alfonso G. Zulueta is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date. As previously reported, Mr. Alfonso resigned as a director on November 29, 2023.